Abstract Library

#3552 Fatigue and quality of life in patients with neuroendocrine neoplasia

Introduction: Neuroendocrine Neoplasms (NEN) are rare tumors and health related quality of life (HRQoL) may be modulated by the disease and the accompanying carcinoid syndrome seen especially in small intestinal NENs. Further, cancer related fatigue is one of the most common side effects of cancer and its treatments and may persist for years after treatment completion.

Conference:

Presenting Author: Hummelshøj N

Authors: Hummelshøj N, Grønbæk H, Bager P, Tabaksblat E, Dam G,

Keywords: Neuroendocrine, HRQoL, Fatigue, Patient reported outcome, Carcinoid syndrome,

#3473 Factors at time of diagnosis associated with progressive or stable disease in patients with Small Intestinal Neuroendocrine Tumors (SI-NETs)

Introduction: EXPLAIN (NCT02630654) is evaluating a multi biomarker strategy for diagnosis, prognosis and response prediction in patients with SI-NET.

Conference:

Presenting Author: Schalin-Jäntti C

Authors: Schalin-Jäntti C, Kjellman M, Knigge U, Grønbæk H, Thiis-Evensen E,

Keywords: SI-NET, Biomarker, Progression, Data mining,

#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours

Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Belusa R

Authors: Knigge U, Kjellman M, Grønbæk H, Thiis-Evensen E, Schalin-Jäntti C,

Keywords: prediction, progression, machine learning, SI-NET, serum protein,

#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm

Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,

Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,

#2190 A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors

Introduction: Retrospective studies showed that changes in plasma chromogranin A (CgA) might predict change in tumor burden in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dam G, Grønbæk H, Sørbye H, Thiis-Evensen E, Paulsson B,

Keywords: gep-net, ct, cga, correlation,